Abcam (NASDAQ:ABCM) Receives New Price Target of 2,200 GBX at Royal Bank of Canada
Abcam (NASDAQ:ABCM – Get a rating) had its price target raised by Royal Bank of Canada research analysts from 1,700 GBX ($20.54) to 2,200 GBX ($26.58) in a research report published on Wednesday, reports The Fly.
Separately, Panmure Gordon upgraded Abcam from a “hold” rating to a “buy” rating in a Monday, September 5 research note.
Abcam share performance
The NASDAQ ABCM rose $0.45 on Wednesday, hitting $16.17. 1,274 shares of the company were traded, against an average volume of 163,874. The company’s fifty-day moving average price is $14.82 and its 200-day moving average price is $15.54. Abcam has a fifty-two week low of $12.54 and a fifty-two week high of $24.00.
Hedge funds weigh on ABCam
Several hedge funds have recently bought and sold shares of ABCM. HM Payson & Co. purchased a new stake in Abcam during Q4 for approximately $29,000. 1832 Asset Management LP bought a new position in Abcam stock in Q1 worth about $32,000. National Bank of Canada FI increased its position in Abcam shares by 71.3% in the second quarter. National Bank of Canada FI now owns 2,777 shares of the company valued at $40,000 after purchasing an additional 1,156 shares during the period. JPMorgan Chase & Co. increased its position in Abcam shares by 48.7% in the first quarter. JPMorgan Chase & Co. now owns 3,044 shares of the company valued at $56,000 after purchasing an additional 997 shares during the period. Finally, Advisor Group Holdings Inc. increased its position in Abcam shares by 20.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 5,876 shares of the company valued at $138,000 after purchasing an additional 999 shares during the period. Institutional investors and hedge funds hold 11.82% of the company’s shares.
Abcam Company Profile
(Get a rating)
Abcam plc, a life sciences company, is focused on the identification, development and distribution of reagents and tools for scientific research, diagnostics and drug discovery. Its main products include primary and secondary antibodies; conjugate antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides including cytokines; modified cell lines and lysates; and various other products, including cell activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Abcam, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes big…and Abcam wasn’t on the list.
While Abcam currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here